1. Home
  2. FRPH vs MYGN Comparison

FRPH vs MYGN Comparison

Compare FRPH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FRP Holdings Inc.

FRPH

FRP Holdings Inc.

HOLD

Current Price

$24.55

Market Cap

420.6M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.66

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRPH
MYGN
Founded
1986
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.6M
444.2M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
FRPH
MYGN
Price
$24.55
$4.66
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$7.64
AVG Volume (30 Days)
45.0K
1.4M
Earning Date
04-10-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$42,846,000.00
$771,400,000.00
Revenue This Year
N/A
$6.86
Revenue Next Year
N/A
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
2.57
2.33
52 Week Low
$20.53
$3.53
52 Week High
$27.71
$8.59

Technical Indicators

Market Signals
Indicator
FRPH
MYGN
Relative Strength Index (RSI) 66.94 57.65
Support Level $22.99 $4.24
Resistance Level $24.53 $4.92
Average True Range (ATR) 0.50 0.29
MACD 0.02 0.03
Stochastic Oscillator 97.65 79.20

Price Performance

Historical Comparison
FRPH
MYGN

About FRPH FRP Holdings Inc.

FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: